Trial Profile
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Aug 2019
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2019 to 1 Sep 2019.
- 24 Jun 2019 Planned End Date changed from 21 Mar 2021 to 1 Apr 2022.
- 24 Jun 2019 Planned primary completion date changed from 21 Mar 2021 to 1 Apr 2022.